Objective ConquerFear is a metacognitive intervention for fear of cancer recurrence (FCR) with proven efficacy immmediately and 6 months post‐treatment. This qualitative study documented barriers and facilitators to the sustainability of ConquerFear from the perspective of study therapists. Methods Fourteen therapists who had delivered ConquerFear in a randomised controlled trial completed a semi‐structured phone interview, reaching theoretical saturation. Themes from thematic analysis were mapped to the Promoting Action on Research Implementation in Health Services (PARiHS) implementation framework. Results Participants were 13 males and one female with, on average, 14 years psycho‐oncology experience. Nine over‐arching themes were identified, falling into three domains, which when present, were facilitators, and if absent, were barriers: evidence (intervention credibility, experienced efficacy, perceived need for intervention); context (positive attitude to and capacity for survivorship/FCR care, favourable therapist orientation and flexibility, strong referral pathways); and facilitation of implementation (intervention/service fit, intervention/patient fit, and training, support, and provided resources). Conclusions ConquerFear is a sustainable intervention in routine clinical practise. Facilitators included a sound evidence base; a receptive context; good fit between the intervention, therapist orientation, and patient need; and flexibility of delivery. Where absent, these factors served as barriers. These results have implications for enhancing uptake of psycho‐oncology interventions in routine care.

Our findings suggest growing use of PROs in the assessment of health and interventions in ANZ. Our review identifies trial categories with limited patient-reported information and provides a basis for future work on the impact of PRO findings in clinical care.

No abstract

No abstract

e21597 Background: Changes to sexual wellbeing can negatively impact long-term quality of life for cancer patients and their partners. Rekindle is an online intervention aimed to provide accessible and tailored psychosexual support to cancer survivors. This study aimed to assessed the feasibility of delivering psychosexual support via Rekindleto cancer survivors and partners who self-report unmet sexual concerns. Methods: This phase II feasibility study, recruited Australian adult cancer survivors who had completed primary therapy > 6 months earlier and/or their partners. Participants were randomized 1:2:1 ratio to either: i) wait list control (WC); ii) Rekindle (10-week online intervention addressing psychoeducational sexual communication and function) (Int); iii) Rekindle Plus ( Rekindleintervention plus three support telephone calls) (Int+). Intervention ran for 10 weeks, after which WC group had access to Int. Participants completed assessments at baseline (T1), intervention end/10 weeks (T2), and six months (T3). The primary feasibility endpoint was the proportion of participants completing prescribed intervention modules. Results: Nov 2015-Dec 2016, 100 participants were randomized: WC: 19, Int: 54, Int+: 27. Baseline characteristics were matched across groups. 57% were male and 91% cancer survivors; 46% had prostate and 23% breast cancer. Participants were prescribed a mean of 6.5 out of 7 modules based on self-reported unmet sexual needs. They completed mean of 1.9 (Int) and 2.5 (Int+) modules with 30% (Int) and 38% (Int+) completed within 10 weeks. A high proportion of users (94%, 100%) commenced Module 1 (Foundations). The largest drop-out between occurred between Modules 1 and 2. Once started, the majority of participants completed each module (76-100%). The mean number of days taken to complete each module varied (4-14 days). Factors impacting engagement with the intervention will also be reported. Conclusions: This phase II study has demonstrated: a need for psychosexual support amongst cancer survivors, that it is feasible to recruit them into an online sexual support study, and to deliver online psychoeducational content for sexual concerns. Clinical trial information: ACTRN12614001245684.

In the original publication of the article, the sentence "The ANZCTR is the fifth largest trial registry internationally, with 21,330 registered trials as at January 2018 [5]" in the Introduction section was published incorrectly.